Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1] Datasheet

Biological Description

Specificity	Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1] detects endogenous levels of total Jak2 protein only when it is phosphorylated at Tyr1007/1008.
Background	Phospho-Jak2 (Tyr1007/1008) represents the critical activation loop phosphorylation within the Janus kinase 2 (Jak2), a non-receptor tyrosine kinase of the Jak family that associates constitutively with cytokine receptors spanning class I and type II families to transduce signals for hematopoiesis, immune regulation, and growth. Jak2 comprises FERM, SH2, and pseudokinase (JH2) domains that maintain autoinhibition until ligand-induced dimerization, with the Tyr1007/1008 motif in the JH1 kinase domain undergoing trans-autophosphorylation to unlock catalytic competency. Ligand binding, such as erythropoietin to EPOR or interferon-γ to IFNGR, clusters receptors, relieving JH2 inhibition and enabling sequential Tyr1007/1008 phosphorylation that amplifies Jak2 activity over 100-fold, recruiting SH2-domain proteins like STAT1/3/5 for tyrosine phosphorylation, dimerization, and nuclear translocation to drive transcription of target genes including SOCS feedback inhibitors, IRF1, and BCL-XL. This cascades through the Jak2-STAT axis with PI3K-Akt and MAPK branches via receptor docking sites, while negative regulation by PTPN6/SHP1 dephosphorylates the loop and SOCS3 binds phosphorylated Tyr221 to attenuate signaling duration. Phospho-Tyr1007/1008 governs erythroid maturation, Th1 differentiation, and megakaryocyte development, positioning it as a direct pharmacodynamic marker for researchers assessing cytokine pathway fidelity in primary hematopoietic cultures or dissecting hypersensitivity in CRISPR-edited cell lines. Dysregulation through the V617F mutation causes constitutive activation in myeloproliferative neoplasms like polycythemia vera.

Specificity

Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1] detects endogenous levels of total Jak2 protein only when it is phosphorylated at Tyr1007/1008.

Background

Phospho-Jak2 (Tyr1007/1008) represents the critical activation loop phosphorylation within the Janus kinase 2 (Jak2), a non-receptor tyrosine kinase of the Jak family that associates constitutively with cytokine receptors spanning class I and type II families to transduce signals for hematopoiesis, immune regulation, and growth. Jak2 comprises FERM, SH2, and pseudokinase (JH2) domains that maintain autoinhibition until ligand-induced dimerization, with the Tyr1007/1008 motif in the JH1 kinase domain undergoing trans-autophosphorylation to unlock catalytic competency. Ligand binding, such as erythropoietin to EPOR or interferon-γ to IFNGR, clusters receptors, relieving JH2 inhibition and enabling sequential Tyr1007/1008 phosphorylation that amplifies Jak2 activity over 100-fold, recruiting SH2-domain proteins like STAT1/3/5 for tyrosine phosphorylation, dimerization, and nuclear translocation to drive transcription of target genes including SOCS feedback inhibitors, IRF1, and BCL-XL. This cascades through the Jak2-STAT axis with PI3K-Akt and MAPK branches via receptor docking sites, while negative regulation by PTPN6/SHP1 dephosphorylates the loop and SOCS3 binds phosphorylated Tyr221 to attenuate signaling duration. Phospho-Tyr1007/1008 governs erythroid maturation, Th1 differentiation, and megakaryocyte development, positioning it as a direct pharmacodynamic marker for researchers assessing cytokine pathway fidelity in primary hematopoietic cultures or dissecting hypersensitivity in CRISPR-edited cell lines. Dysregulation through the V617F mutation causes constitutive activation in myeloproliferative neoplasms like polycythemia vera.

Usage Information

Application

WB

Dilution

WB

1:1000

Reactivity

Human, Mouse, Rat

Source

Rabbit Monoclonal Antibody

MW

125 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/19364823/
https://pubmed.ncbi.nlm.nih.gov/15143188/

Application Data

WB

Validated by Selleck

Lane 1: UT-7, Lane 2: UT-7 (GM-CSF treated)